Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

PDX models of relapsed pediatric AML preserve global gene expression patterns and reveal therapeutic targets

ABSTRACT: PDX models of relapsed pediatric AML preserve global gene expression patterns and reveal therapeutic targets

PROVIDER: PRJNA1063296 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR27483114.fastq.gz	Fastqsanger.gz
	SRR27483115.fastq.gz	Fastqsanger.gz
	SRR27483116.fastq.gz	Fastqsanger.gz
	SRR27483117.fastq.gz	Fastqsanger.gz
	SRR27483118.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 47

Similar Datasets

PDX models of relapsed pediatric AML preserve global gene expression patterns and reveal therapeutic targets

Project description:Patient-derived xenograft (PDX) models are commonly used for preclinical evaluation of targeted therapies. It is important to consider the fidelity with which these systems recapitulate the patient disease state. Currently, there is little information regarding how well pediatric AML PDXs mimic the global gene expression found in patients. Here we analyzed RNAseq data from a diverse series of high-risk pediatric AML PDXs, separately and compared to primary patient data. Unsupervised clustering of PDX data resulted in segregation according to KMT2A (MLL) status. Combined analysis showed PDX samples aligned with patient samples harboring similar genetics. Among KMT2A rearranged samples, we observed strong correlation of expression levels of nearly all expressed transcripts. Furthermore, matched patient/PDX pairs showed strong concordance, suggesting retention of sample-specific gene expression. Interestingly, our analysis uncovered previously unidentified cryptic CBFA2T3-GLIS2 rearrangement in two PDX models. Based on high BCL2 mRNA in these models, we tested the efficacy of venetoclax in combination with chemotherapy. While standard daunorubicin/ara-C treatment failed to produce benefits, CPX-351 decreased disease burden and prolonged survival, particularly when combined with venetoclax. These results validate PDX modeling of high-risk pediatric AML and highlight this system's utility for pre-clinical therapeutic discovery, especially for rare subtypes of disease.

2025-01-09 | GSE252945 | GEO

Gene expression profiles associated with pediatric relapsed AML

Project description:In high income countries 90% of the patients achieve complete remission after induction chemotherapy. However, 30-40% of these patients suffer from relapse. These patients face a dismal prognosis, as the majority (>60%) of relapsed patients die within 5 years. As a result, outcome for pediatric acute myeloid leukemia (AML) patients remains poor and has stabilized over the past 15 years. To prevent or better treat relapse of AML is the best option to improve outcome. Despite patient specific differences, most patients do respond to initial therapy. This suggests that at relapse, mechanisms are active that cause the altered response to chemotherapy. Detailed understanding of mechanisms that cause relapse remain largely elusive. To gain insight in the molecular pathways that characterize relapsed AML, we performed genome wide gene expression profiling on paired initial diagnosis and relapsed AML samples of 23 pediatric AML patients. We used pathway analysis to find which molecular pathways are involved in altered gene expression between diagnosis and relapse samples of individual AML patients. 23 paired diagnosis and relapse bone marrow or peripheral blood samples were collected and cryo-preserved. They were later thawed and processed for hybridization to Affymetrix U133 Plus 2.0 arrays.

2015-05-07 | E-GEOD-52891 | biostudies-arrayexpress

Gene expression profiles associated with pediatric relapsed AML

2015-05-07 | GSE52891 | GEO

DNA methylation of Relapsed/Refractory AML

Project description:DNA methylation of Relapsed/Refractory AML

| PRJNA934390 | ENA

Genotyping of human AMP patients using 27 pairs of diagnostic and relapsed AML samples

Project description:Relapse is the commonest cause of death in acute myeloid leukaemia (AML), but the mechanisms leading to relapse are unclear. Recently, acquisition of segmental uniparental disomy (UPD) by mitotic recombination (MR) has been reported in 15-20% of AML samples at diagnosis using whole genome single nucleotide polymorphism (SNP) arrays. These cytogenetically invisible abnormalities are associated with homozygous mutations in several types of malignancy. Clonal evolution of heterozygous to homozygous mutations by MR could provide a mechanism for relapse. Experiment Overall Design: DNA from 27 pairs of diagnostic and relapsed AML samples were analysed using Affymetrix 10K SNP arrays. The genotype data of relapsed AML were compared with the data from the corresponding presentation AML.

2008-06-15 | E-GEOD-7210 | biostudies-arrayexpress

Targeting mitochondrial apoptotic priming state to personalize therapy for relapsed acute myeloid leukemia

Project description:The majority of relapsed acute myeloid leukemia (AML) patients still succumb to disease despite improvements in therapy. We present landscapes of pharmacologic sensitivity for 22 AML patient-derived xenograft (PDX) models together with genomic and transcriptomic profiles. First, we used ex vivo dynamic BH3 profiling (DBP) to segregate PDXs according to prior treatment status and accurately predicted in vivo efficacy of drugs with varying mechanisms of action. We next selected in vivo acquired resistance to single agents of distinct mechanisms, which caused broad chemoresistance across all models associated with a reduction in mitochondrial apoptotic priming. DBP could identify drugs with persistent in vivo activity even in these resistant models. Using RNA-seq, we found conserved gene expression signatures defining relapsed phenotypes common to mechanistically distinct agents targeting FLT-3, BCL2, IAPs, and BRD-4. We replicated drug-response patterns from PDX models in primary and relapsed AML patients, demonstrating the clinical feasibility of such approach

2024-02-15 | GSE237794 | GEO

RNA sequencing of PDX-AML samples using prime-seq

Project description:We established serially transplantable and robust, genetically engineered patient derived xenograft (PDX) models of acute myeloid leukemia (AML).

2025-09-18 | GSE307747 | GEO

Methylation profiling of PDX-AML samples using Illumina Infinium MethylationEPIC BeadChips

Project description:We established serially transplantable and robust, genetically engineered patient derived xenograft (PDX) models of acute myeloid leukemia (AML).

2025-09-25 | GSE308997 | GEO

Transcriptomic profiling of MLL-r AML PDX cells treated with CDKI-73 and/or JQ1

Project description:Transcriptomic profiling of MLL-r AML PDX cells treated with CDKI-73 and/or JQ1

2020-02-03 | GSE129449 | GEO

RNA sequencing of PDX-AML samples using prime-seq

Project description:RNA sequencing of PDX-AML samples using prime-seq

| PRJNA1327255 | ENA